HCC surveillance: Who is the target population?

Jordi Bruix; Josep M. Llovet

doi:10.1053/jhep.2003.50142

Related publications

Article2015

P0265 : IGF2 is an oncogenic driver in HCC and emerges as a potential target for therapies

Iris Martinez-Quetglas, Roser Pinyol, Daniel Dauch, Anna Portela, Judit Peix, Mónica Higuera, Jessica Zucman‐Rossi, Manel Esteller, Vincenzo Mazzaferro, Lars Zender, Josep M. Llovet

Journal of Hepatology

Article2016

Re-Expression of Fetal Igf2 as Epidriver and Target for Therapy in Hcc

Iris Martinez-Quetglas, Roser Pinyol, Daniel Dauch, Sara Torrecilla, Victoria Tovar, Agrin Moeini, Clara Alsinet, Silvana Bonilla, Anna Portela, Leonardo Rodríguez‐Carunchio, María A. Solé, A. Villanueva, Manel Esteller, Lars Zender, Josep M. Llovet

Journal of Hepatology

Article2014

466 IGF2 drives IGF oncogenic signaling in HCC and emerges as a potential target for therapies

I.M. Quetglas, Roser Pinyol, Daniel Dauch, Anna Portela, Alberto Villanueva, Judit Peix, María Ángeles Moreno de la Higuera, Agrin Moeini, Jessica Zucman‐Rossi, Manel Esteller, Vincenzo Mazzaferro, Lars Zender, Josep M. Llovet

European Journal of Cancer

Article2020

Why is WHO failing women with falciparum malaria in the first trimester of pregnancy?

Rose McGready, François Nosten, Karen I. Barnes, Olugbenga Ayodeji Mokuolu, Sir Nicholas White

The Lancet

Article2008

Applying the new WHO child growth standards in Canada: what is our prevalence of obesity

Mark S. Tremblay, M. Shields